Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Viracta Therapeutics, Inc. VIRX
$1.15
На 18:00, 12 мая 2023
+595.65%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
46093080.00000000
-
week52high
5.75
-
week52low
0.88
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.29121800
-
EPS
-1.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 03 мая 2021 г. | |
| SVB Leerink | Outperform | 26 апр 2021 г. | |
| Evercore ISI Group | Outperform | 25 мар 2021 г. | |
| RBC Capital | Outperform | Outperform | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Chevallard Daniel R. | D | 85733 | 3532 | 28 ноя 2022 г. |
| Rojkjaer Lisa | D | 46116 | 2116 | 28 ноя 2022 г. |
| Chevallard Daniel R. | D | 68888 | 6889 | 25 ноя 2022 г. |
| Chevallard Daniel R. | A | 89265 | 6889 | 25 ноя 2022 г. |
| Rojkjaer Lisa | D | 41273 | 4127 | 25 ноя 2022 г. |
| Rojkjaer Lisa | A | 48232 | 4127 | 25 ноя 2022 г. |
| Pomerantz Roger | D | 90343 | 9034 | 25 ноя 2022 г. |
| Pomerantz Roger | A | 54204 | 9034 | 25 ноя 2022 г. |
| ROYSTON IVOR | D | 252190 | 25219 | 25 ноя 2022 г. |
| ROYSTON IVOR | A | 637989 | 25219 | 25 ноя 2022 г. |
Новостная лента
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
11 мая 2023 г. в 16:05
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT.
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
GlobeNewsWire
19 апр 2023 г. в 16:30
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
GlobeNewsWire
08 мар 2023 г. в 16:05
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the 33rd Annual Oppenheimer Healthcare Conference on Wednesday, March 15, 2023, at 12:00 p.m. ET.
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
GlobeNewsWire
07 февр 2023 г. в 16:05
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
Zacks Investment Research
08 сент 2022 г. в 14:18
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.